argenx SE American Depositary Shares (ARGX) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA...
argenx SE American Depositary Shares (ARGX) currently trades at a P/E ratio of 39.66 (historical range: 33.93–72.74, median: 46.31), placing it at the 8th percentile — cheap relative to its history, P/S ratio of 12.10 (range: 10.35–73.61, 3th percentile — cheap relative to its history), EV/EBITDA of 43.72 (range: 36.69–61.42, 17th percentile).
argenx SE American Depositary Shares trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 39.66 | 46.31 | 8th | cheap relative to its history |
| P/S Ratio | 12.10 | 26.42 | 3th | cheap relative to its history |
| EV/EBITDA | 43.72 | 47.73 | 17th | cheap relative to its history |
| FCF Yield | 1.89% | 1.69% | 89th | cheap relative to its history |
argenx SE American Depositary Shares (ARGX) Valuation & P/E History
argenx SE American Depositary Shares (ARGX) is a US-listed stock operating in the Healthcare sector currently trading at $819.14 with a market capitalization of $51.5 billion. This page provides historical valuation analysis for ARGX based on 1280 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 39.66 is below the historical median of 46.31, placing ARGX at the 8th percentile of its valuation range. The P/S ratio of 12.10 compares to a median of 26.42.
ARGX Valuation Metrics & Historical Range
The valuation table above shows argenx SE American Depositary Shares's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether ARGX is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests ARGX is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for argenx SE American Depositary Shares.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is ARGX Overvalued or Undervalued?
argenx SE American Depositary Shares trades well below its historical valuation range across most metrics. The overall valuation percentile of 9 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive ARGX is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full ARGX analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.ARGX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.